Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL18261423

NC(=O)CCNc1ccc(N2C(=O)C=CC2=O)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 4/20 0.43
▸ DDAH1 O94760 1/20 0.42
▸ MGLL Q99685 11/20 0.40
▸ FAAH O00519 5/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ TLR9 Q9NR96 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ APBA1 Q02410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31031903 0.92 MGLL (0.47) HSP90AA1DDAH1MGLLFAAHNPSR1
Trifluoroacetic Acid SCHEMBL20945171 0.75 DDAH1 (0.54) HSP90AA1DDAH1MGLLFAAHL3MBTL1
Trifluoroacetic Acid SCHEMBL18261456 0.71 DRD2 (0.42) HSP90AA1MGLLFAAHNPSR1TDP1
SCHEMBL1531486 0.69 MAPT (0.52) L3MBTL1ALDH1A1HPGDMAPT
SCHEMBL9720879 0.69 MGLL (0.62) HSP90AA1DDAH1MGLLFAAHNPSR1
SCHEMBL12505801 0.69 MGLL (0.56) HSP90AA1DDAH1MGLLFAAHNPSR1
Hydrochloric Acid SCHEMBL12477635 0.68 MAPT (0.50) L3MBTL1ALDH1A1HPGDMAPT
SCHEMBL11141017 0.68 PEPD (0.50) MAPK1ALDH1A1MAPT
SCHEMBL741572 0.68 MGLL (0.59) HSP90AA1DDAH1MGLLFAAHNPSR1
Water SCHEMBL17644778 0.67 MGLL (0.58) HSP90AA1DDAH1MGLLFAAHNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-02-09 — — US disclosed
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-07-27 — — US disclosed
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-08-18 — — US disclosed
US-20200138970-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-07 — — US disclosed
US-20180318437-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-08 — — US disclosed
US-20180318438-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-08 — — US disclosed
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-17 — — US disclosed
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES Bayer Pharma AG (DE) 2018-07-05 — — US disclosed
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 — — US disclosed
US-20160346402-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies KIF23, KIF2C, KIF18A HSP90AA1 1162/4885DDAH1 3202/4885MGLL 4664/4885
US-20180318438-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES KIF5B, KIF23, KIF2C HSP90AA1 1424/4885DDAH1 3257/4885MGLL 4774/4885
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) KIF5B, KIF23, KIF2C HSP90AA1 1301/4885DDAH1 2975/4885MGLL 4657/4885
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies KIF23, KIF5B, KIF2C HSP90AA1 1659/4885DDAH1 1775/4885MGLL 4836/4885
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES KIF23, KIF5B, KIF2C HSP90AA1 1220/4885DDAH1 2202/4885MGLL 4704/4885
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES TNFSF11, TNFRSF9, CD40 HSP90AA1 2556/4885DDAH1 3020/4885MGLL 4430/4885
US-20200138970-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES KIF23, KIF5B, KIF2C HSP90AA1 1659/4885DDAH1 1775/4885MGLL 4836/4885
US-20160346402-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) KIF5B, KIF23, KIF2C HSP90AA1 1301/4885DDAH1 2975/4885MGLL 4657/4885
US-20180318437-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES KIF23, KIF2C, KIF18A HSP90AA1 1162/4885DDAH1 3202/4885MGLL 4664/4885
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS KIFC1, KIF2C, KIF5B HSP90AA1 2035/4885DDAH1 944/4885MGLL 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback